Search results with tag "Prescribing information"
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use SKYLA safely and effectively. See full prescribing information for SKYLA. SKYLA (levonorgestrel-releasing intrauterine system) Initial U.S. Approval: 2000 •-----RECENT MAJOR CHANGES-----
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.us.astellas.comHIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use MYRBETRIQ ® /MYRBETRIQ ® GRANULES safely and effectively. See full prescribing information for MYRBETRIQ /MYRBETRIQ GRANULES. o. not chew, divide. MYRBETRIQ (mirabegron extended-release tablets), for oral use
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
packageinserts.bms.com13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 15 REFERENCES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed. FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.novartis.usHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KESIMPTA safely and effectively. See full prescribing information for KESIMPTA. or live vaccines is not recommended during treatment with KESIMPTA® (ofatumumab) injection, for subcutaneous use Initial U.S. Approval: 2009
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
media.allergan.comAug 29, 2017 · HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LATISSE safely and effectively. See full prescribing information for LATISSE. LATISSE® (bimatoprost ophthalmic solution) 0.03%, for topical ophthalmic use Initial U.S. Approval: 2001 _____INDICATIONS AND USAGE_____
HIGHLIGHTS OF PRESCRIBING INFORMATION The …
www.regeneron.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRALUENT safely and effectively. See full prescribing information for PRALUENT. ... The mean age of the population was 59 years, 40% of the population were women, 90% were White, 4% were Black or African American, and
ZEPOSIA U.S. Prescribing Information - BMS
packageinserts.bms.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZEPOSIA safely and effectively. See full prescribing information for ZEPOSIA. ZEPOSIA® (ozanimod) capsules, for oral use Initial U.S. Approval: 2020-----RECENT MAJOR CHANGES-----
HIGHLIGHTS OF PRESCRIBING INFORMATION TIVDAK ...
seagendocs.comHIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TIVDAK safely and effectively. See full prescribing information for TIVDAK. TIVDAK ® (tisotumab vedotin -tftv) for injection, for intravenous use Initial U.S. Approval: 2021 • WARNING: OCULAR TOXICITY
HIGHLIGHTS OF PRESCRIBING INFORMATION
www.novartis.usWhen given with KISQALI, refer to the Full Prescribing Information for the recommended dose of the aromatase inhibitor being used. When given with KISQALI, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, 29, and once monthly thereafter. Please refer to the Full Prescribing Information of fulvestrant.
HIGHLIGHTS OF PRESCRIBING INFORMATION • Discontinue …
www.astellas.usof these drugs. If XTANDI is co-administered with warfarin (CYP2C9 substrate), conduct additional INR monitoring. (7.3) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 07/2021 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Dosing Information …
See full prescribing information for complete boxed ...
labeling.bayerhealthcare.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 12/2020 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: HEPATOTOXICITY 1 INDICATIONS AND USAGE 1.1 Colorectal Cancer 1.2 Gastrointestinal Stromal Tumors 1.3 Hepatocellular Carcinoma 2 DOSAGE AND ADMINISTRATION 2.1 …
HIGHLIGHTS •OF PRESCRIBING INFORMATION Do not …
media.allergan.comSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 8/2021 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage 2.2 Preparation …
HIGHLIGHTS OF PRESCRIBING INFORMATION - GSKpro
gskpro.com*Sections or subsections omitted from the full prescribing information are not listed. _____ FULL PRESCRIBING INF ORMATION . 1 INDICATIONS AND USAGE . 1.1 Maintenance Treatment of Chronic Obstructive Pulmonary Disease . TRELEGY ELLIPTA 100/62.5/25 mcg is indicated for the maintenance treatment of patients with chronic obstructive pulmonary ...
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
media.allergan.comSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 11/2018 _____ FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Genitourinary Conditions 6 …
HIGHLIGHTS OF PRESCRIBING INFORMATION LEQVIO …
www.novartis.usSee 17 for PATIENT COUNSELING INFORMATION. Revised: 12/2021 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage 2.2 Important Administration Instructions 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 6 ADVERSE REACTIONS …
and consider a change in treatment
www.gene.comHemophilia A without FVIII Inhibitors Hemophilia A with FVIII Inhibitors 16 HOW SUPPLIED/STORAGE AND HANDLING PATIENT COUNSELING INFORMATION * Sections or subsections omitted from the full prescribing information are not listed. WARNING: THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM . See full prescribing …
Berinert Prescribing Information - CSL Behring
labeling.cslbehring.comCSL Behring FULL PRESCRIBING INFORMATION BERINERT® [C1 Esterase Inhibitor (Human)] Freeze-dried powder 1 INDICA TIONS AND USAGE BERINERT is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients.
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.kineretrx.comSee full prescribing information for administration instructions (2.4) -----DOSAGE FORMS AND STRENGTHS----- Injection: 100 mg/0.67 mL solution in a single-use prefilled syringe for subcutaneous injection. Graduated syringe allows for doses between 20 mg and 100 mg. (3) ...
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.ilumya.comFULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Dosage 2.2 Tuberculosis Assessment Prior to Initiation of ILUMYA 2.3 Important Administration Instructions 2.4 Preparation and Administration of ILUMYA 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND …
HIGHLIGHTS OF PRESCRIBING INFORMATION Men with ... - …
www.xyosted.comSee full prescribing information for complete boxed warning • XYOSTED can cause blood pressure (BP)increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death (5.1, 6.1). • Before initiating XYOSTED, consider the patient’s baseline
HIGHLIGHTS OF PRESCRIBING INFORMATION • IMLYGIC …
www.pi.amgen.comadvised to follow standard hygienic practices to prevent viral . (5.2) • Injection Site Complications: Consider the risks and benefits before ... FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE IMLYGIC is a genetically modified oncolytic viral therapy indicated for …
HIGHLIGHTS OF PRESCRIBING INFORMATION
www.lenvima.comFULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Differentiated Thyroid Cancer LENVIMA is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated …
PIQRAY (alpelisib) tablets, for oral use (Grade ≤ 2 ...
www.novartis.usSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 7/2021 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Patient Selection 2.2 Dosage and Administration 2.3 Dose Modifications for Adverse Reactions 3 DOSAGE FORMS AND …
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.gene.com----- DRUG INTERACTIONS ----- Live attenuated influenza vaccine (LAIV), intranasal: Avoid administration of LAIV within 2 weeks before or 48 hours after TAMIFLU use, unless medically indicated. (7) See . 17. for PATIENT COUNSELING INFORMATION and …
Farxiga Prescribing Information
den8dhaj6zs0e.cloudfront.netUrosepsis and Pyelonephritis: Evaluate for signs and symptoms of urinary tract : infections and treat promptly, if indicated. (5.3) • Hypoglycemia: Consider a lower dose of insulin or the insulin secretagogue to reduce: the risk of hypoglycemia when used in combination with FARXIGA. (5.4)
HIGHLIGHTS OF PRESCRIBING INFORMATION - Amgen
www.pi.amgen.com5.5 Atypical Subtrochanteric and Diaphyseal Femoral Fracture 5.6 Hypercalcemia Following Treatment Discontinuation in Patients with Giant Cell Tumor of Bone and in Patients with Growing Skeletons 5.7 Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation 5.8 Embryo-Fetal Toxicity 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.merck.comN=786 % Placebo with SoC‡ N=781 % Gastrointestinal disorders Nausea 7% 5% General disorders and administration site conditions Pyrexia 5% 3% Nervous system disorders Headache 4% 3% * All patients as treated population, defined as all randomized patients who received a dose of study medication, by treatment received
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
labeling.bayerhealthcare.com4 • Interval insertion following complete involution of the uterus • Wait a minimum of 6 weeks or until the uterus is fully involuted before inserting Kyleena [see Warnings and Precautions (5.5, 5.6), Adverse Reactions (6.2)]. • Insert Kyleena any time there is reasonable certainty the woman is not pregnant. • If Kyleena is not inserted during the first 7 days of the menstrual cycle, a
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE …
www.rxabbvie.comantirheumatic drugs (DMARDs). 2.3 Procedures Prior to Treatment Initiation Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with SKYRIZI [see Warnings and Precautions (5.3)]. Complete all age-appropriate vaccinations as recommended by current immunization guidelines [see Warnings and Precautions (5.4)].
HIGHLIGHTS OF PRESCRIBING INFORMATION and platelet …
pp.jazzpharma.comBased on animal data and its mechanism of action ZEPZELCA can cause fetal harm when administered to a pregnant woman. Intravenous administration of a single dose of lurbinectedin (approximately 0.2 times the 3.2 mg/m 2 clinical dose) to pregnant animals during the period of organogenesis caused 100% embryolethality in rats.
HIGHLIGHTS OF PRESCRIBING INFORMATION Still’s disease ...
www.novartis.usInfections, predominantly of the upper respiratory tract, in some instances serious, have been reported with ILARIS. Generally, the observed infections responded to standard therapy. Isolated cases of unusual or opportunistic infections (e.g., aspergillosis, atypical mycobacterial infections, cytomegalovirus, herpes zoster)were reported during ...
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.supernus.comemerging suicidal ideation or behavior. Thus, patients being treated with Qelbree should be observed for the ... In a clinical study in patients 12 to 17 years of age, 22/99 (22%) of patients treated with Qelbree 200 mg daily had a ≥20 bpm increase in heart rate at any time point in the clinical trial, compared to 15/104 (14%) of patients who ...
IMBRUVICA. IMBRUVICA PRC-07470
www.imbruvica.com2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Mantle Cell Lymphoma IMBRUVICA is indicated for the treatment of …
BREYANZI (lisocabtagene maraleucel) suspension for ...
packageinserts.bms.com1 2.INDICATIONS AND USAGE BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell ... See the prescribing information for fludarabine and cyclophosphamide for
HIGHLIGHTS OF PRESCRIBING INFORMATION Platinum …
www.pi.amgen.comPlatinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (2.7) • 15 mg/kg every 3 weeks with carboplatin and paclitaxel for 6-8 cycles, ... demonstrating that it is highly similar to an FDA-approved biological product,
HIGHLIGHTS OF PRESCRIBING INFORMATION • Chronic …
www.novartis.usPlatelet Count Result Dose Adjustment or Response < 50 9x 10 /L following at least 2 weeks of PROMACTA . Increase daily dose by 25 mg to a maximum of 75 mg/day. For patients taking 12.5 mg once daily, increase the dose to 25 mg daily before increasing the dose amount by 25 mg.
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.gilead.comInitial U.S. Approval: 2020 activities, such as operating heavy or potentially dangerous ... 2.3 Management of Severe Adverse Reactions 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Cytokine Release Syndrome 5.2 Neurologic Toxicities 5.3 YESCARTA and TECARTUS REMS Program ...
Similar queries
HIGHLIGHTS OF PRESCRIBING INFORMATION • These, HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights, INFORMATION, PRESCRIBING INFORMATION, See full prescribing information, PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE, HIGHLIGHTS OF PRESCRIBING INFORMATION These, HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights, HIGHLIGHTS OF PRESCRIBING INFORMATION, Highlights, ZEPOSIA, Please, Warfarin, 1 INDICATIONS AND USAGE 1, PATIENT COUNSELING, PRESCRIBING INF ORMATION, 1 INDICATIONS AND USAGE, FULL PRESCRIBING INFORMATION, Treatment, Hemophilia, Prescribing, CSL Behring, WARNINGS, Standard, PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1, INTERACTIONS, Urosepsis, Diaphyseal, Antirheumatic drugs, Mechanism, Infections, Mycobacterial infections, Emerging, BREYANZI, INDICATIONS AND USAGE BREYANZI, Sensitive, Highly, Platelet Count, Initial, Management